Clinical Trial Update: Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]

View source ↗

Summary

Phase 3 efficacy study of GlaxoSmithKline's investigational RSV vaccine in adults aged 60 years and older has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GSK RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2023-08-04